RECORDS ARE PUBLISHED REGULATORY ACTIONS. FIELDS THE ISSUING AUTHORITY DID NOT PUBLISH ARE MARKED AS NOT STATED, NEVER FILLED IN.
Drug Eye AfricaNational Actions, Continental Reach
Manufacturer profile

CMO - Novartis Pharma S.A.E, Cairo, Egypt for Sandoz

Every published regulatory action recorded against this manufacturer, across all African authorities Drug Eye Africa monitors. Built strictly from published regulatory decisions and nothing else.

What these numbers are. They are counts of published regulatory actions recorded on this register. They are not a finding about the company, not an allegation, and not a measure of product quality. A manufacturer appearing here has had actions published against named products by named authorities; the actions speak for themselves and each one links to its primary notice.
1
Recorded actions
1
Countries
1
Authorities
0
Class I actions recorded

Recorded actions

1 shown
ReferenceDateCountryProductBatchesActionClassSource
DEA-EG-2026-0001Jan 2026EGDiclacAmpoule 75 mg
CMO - Novartis Pharma S.A.E, Cairo, Egypt for Sandoz
Y0011RecallClass IITier 1 · Regulator-published

Counts are of published regulatory actions recorded on this register. They are not a finding about the company, and this page says so.

Names as published

The issuing authorities published this name as: CMO - Novartis Pharma S.A.E, Cairo, Egypt for Sandoz.

Company response

Drug Eye Africa has not yet invited a response from this company. That is our omission and not the company’s silence, and it is recorded here as one.

A company named on this page may write to notices@drugeyeafrica.org. A response is published beside these records in full, and the request is logged either way. Nothing on this page is a finding about the company: each entry is an action a named authority published, and it links to that authority’s own notice.

How this page is built

  • Published regulator decisions only — no press reports, no allegations
  • Name matching is conservative: only corporate-form suffixes are stripped, and a name that would reduce to a single token is kept whole
  • Every action links to its primary notice
CMO - Novartis Pharma S.A.E, Cairo, Egypt for Sandoz · Drug Eye Africa